ReviewJournal of the American Geriatrics Society2010
The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis.
Review in Journal of the American Geriatrics Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The Effects of Cow-Milk Protein Supplementation in Elderly Population: Systematic Review and Narrative Synthesis.Nutrients · 2020Pooled it
- Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2013Trial
- Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.The European respiratory journal · 2012Trial
- The association between systemic immune-inflammation index and mortality of elderly chronic bronchitis patients complicated by acute myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Tuberculosis patients' delay in healthcare access and its associated factors in Shandong Province, China.BMC public health · 2025Article
- Analyzing Clinical Parameters and Bacterial Profiles to Uncover the COPD Exacerbations: A Focus on Intensive Care Unit Challenges.Medicina (Kaunas, Lithuania) · 2025Article
- Poor treatment outcomes of acute exacerbations of chronic obstructive pulmonary disease and their associated factors among admitted patients in East Gojjam, 2023.Frontiers in medicine · 2024Article
- Sputum culture and antibiotic resistance in elderly inpatients with exacerbation of chronic obstructive pulmonary disease at a tertiary geriatric hospital in southern Vietnam.Aging clinical and experimental research · 2023Article
- Article
- Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice-The "AIOLOS" Study.Canadian respiratory journal · 2021Observational
- Inappropriate Utilization of Antibiotics in COPD Exacerbations.Turkish thoracic journal · 2020Article
- NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma.Frontiers in immunology · 2019Review
- Midkine is expressed and differentially processed during chronic obstructive pulmonary disease exacerbations and ventilator-associated pneumonia associated with Staphylococcus aureus infection.Molecular medicine (Cambridge, Mass.) · 2013Article
- Utility of NT-proBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis.PloS one · 2013Article
- Respiratory impairment and COPD hospitalisation in older persons: a competing risk analysis.The European respiratory journal · 2012Article
- First comprehensive evaluation of the M.I.C. evaluator device compared to Etest and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species.Journal of clinical microbiology · 2012Article
- [Pulmonary diseases in the elderly].Zeitschrift fur Gerontologie und Geriatrie · 2011Article
- Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.Pulmonary medicine · 2011Article
- Defining chronic obstructive pulmonary disease in an aging population.Journal of the American Geriatrics Society · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The syndrome of chronic obstructive pulmonary disease (COPD) consists of chronic bronchitis (CB), bronchiectasis, emphysema, and reversible airway disease that combine uniquely in an individual patient. Older patients are at risk for COPD and its components--emphysema, CB, and bronchiectasis. Bacterial and viral infections play a role in acute exacerbations of COPD (AECOPD) and in acute exacerbations of CB (AECB) without features of COPD. Older patients are at risk for resistant bacterial organisms during their episodes of AECOPD and AECB. Organisms include the more-common bacteria implicated in AECOPD/AECB such as Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Less-common nonenteric, gram-negative organisms including Pseudomonas aeruginosa, gram-positive organisms including Staphylococcus aureus, and strains of nontuberculosis Mycobacteria are more often seen in AECOPD/AECB episodes involving elderly patients with frequent episodes of CB or those with bronchiectasis. Risk-stratified antibiotic treatment guidelines appear useful for purulent episodes of AECOPD and episodes of AECB. These guidelines have not been prospectively validated for the general population and especially not for the elderly population. Using a risk-stratification approach for elderly patients, first-line antibiotics (e.g., amoxicillin, ampicillin, pivampicillin, trimethoprim/sulfamethoxazole, and doxycycline), with a more-limited spectrum of antibacterial coverage, are used in patients who are likely to have a low probability of resistant organisms during AECOPD/AECB. Second-line antibiotics (e.g., amoxicillin/clavulanic acid, second- or third-generation cephalosporins, and respiratory fluoroquinolones) with a broader spectrum of coverage are reserved for patients with significant risk factors for resistant organisms and those who have failed initial antibiotic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.